Zach Reitano - Building Ro and Why Healthcare Should Be 50% of GDP - [Invest Like the Best, EP.500]

1. Key Themes

The Patient Is Not the Customer, and That Is the Root Flaw of US Healthcare

Reitano argues the single central flaw is incentive misalignment: whoever controls money at the point of purchase is the customer, and in healthcare that is almost never the patient. He claims the places where healthcare "works" are precisely the cash-pay places.

Zach Reitano: "if I had to say what is the problem with our healthcare system, it is that the patient is not the customer. That's the problem that we're trying to solve at Ro" 00:05:48. He adds: "You look at LASIK eye surgery. Costs come down, quality improves, convenience improves. You look at breast augmentation, you look at cosmetic surgeries. Costs come down, quality improves, convenience improves." 00:06:58 His strategic thesis: "if we can aggregate patient spend, I think we can bend the healthcare system to the will of patients." 00:10:16

GLP-1s as the Wedge That Rewires the Healthcare System (Direct-to-Consumer, Disintermediating PBMs)

GLP-1s are the cleanest case study of a cash-pay market delivering transparency, lower prices, and higher volume at once. Middlemen are being stripped out while manufacturers make more money.

Zach Reitano: "Prices go from $1,300 to $149, and the people making the drugs are making more money." 00:08:08 On PBMs: "PBMs, to me, they are like the appendix of the healthcare system. At one point in time, they might've served some purpose, but it was so long ago that people can't remember what the heck it was. And turns out when you remove them from the equation, software can do exactly what they would've done historically." 00:07:30 He also frames the policy lesson: "Politicians and regulators have been trying to get transparent prices for 20, 25 years. What happens? Pharma goes direct." 00:06:58 And: "You are going to see GLP-1s rewire... Prices are transparent, they're coming down, there's more competition." 00:18:10

Health Spend Should Be a Growing Share of GDP, Not a Shrinking One

Reitano reframes the "18% of GDP is a crisis" narrative as a Jevons' paradox opportunity: the problem is cost per unit and outcomes, not the absolute share.

Zach Reitano: "the only good in our lives that does not have any diminishing marginal return is another healthy year. And so, to me, at the limit, you should be spending every single dollar towards the health of your society." 00:01:58 He also argues spend is hyper-concentrated: "We spend probably 50% of our healthcare costs on 5% of people." 00:02:31 And that the US is a preview: "UK... went from 6 to 12. You look at Germany, went from 9 to 12. You look at the US, it went from 9 to 18." 00:03:07

Ro as a Vertically Integrated, Condition-Agnostic "Care Distribution Platform"

Ro grew from roughly a $250M run rate to over $3B in four years, and the platform was built before GLP-1s arrived, which let it expand fast when the wave hit.

Zach Reitano: "we built an EMR from scratch. We built our own CLIA-certified CAP-accredited lab. We built our own pharmacies. We built our own pharmacy software. We built our own provider network. All of those are seamlessly integrated and they are built in a condition-agnostic way." 00:13:45 And: "they actually should just think about a world-class care and treatment distribution platform that is all vertically integrated, custom-built software in service of helping that patient achieve their health goals." 00:14:18 Differentiation, in his view, is purely a treadmill: "the only, only, only source of differentiation is continued innovation." 00:13:15

Three Tailwinds: Biology Online, "Specialist Becomes a Prompt," and Treatments That Shift Quantity and Quality of Life

Beyond GLP-1s, Reitano lays out a structural thesis for a "patient revolution."

Zach Reitano: "number one tailwind, biology coming online... Number two, what used to require a specialist, now requires a prompt... Third is, there are now treatments that do radically shift the quality and quantity of people's lives. They're just not evenly distributed." 00:44:11 On investor behavior: "they're paying $100K a year for a concierge doctor, and they ping Claude for 20 bucks a month, and it's way better." 00:44:11 And the ambition: "we can get a whole new form of healthcare for the price of Netflix." 00:44:11

The Refounding: Strong-Attract, Strong-Repel Culture as an Operating System

After raising $500M at a $5B valuation in January 2021, Ro grew just 9% that year and sat on an ~$800M pref stack. Reitano's fix was explicit culture, ruthless talent standards, and focus.

Zach Reitano: "We confused our long-term vision with our near-term strategy and we decided to do everything and hire everyone and try to do everything all at once." 00:29:24 The fix: "fully embracing a strong-attract and strong-repel culture." 00:31:59 Outcome: "We were 600 people when I was on that plane. We're now 400 and change, and we've 10x-ed the business. So, we've 10x-ed the business with 30% fewer people." 00:36:18

Consumer Healthcare Marketing: Permission Structures, Stigma as Latent Demand, and Authentic Celebrity

Ro treats stigma as stored potential energy and uses famous, authentically-on-product faces to shift the Overton window.

Zach Reitano: "what our marketing does is it tries to create permission structures on behalf of people who need that product or service by doing two things, massively shifting the Overton window so that we're the extreme so that they never have to be." 01:00:38 On stigma: "There's a lot of potential energy there." 01:04:55 On why celebrities matter more in the AI era: "Well, you see Charles Barkley's face, or Serena's face, or Megan Fox's. You cannot replicate those in an age of AI." 01:09:29

Slow-Clock vs. Fast-Clock Death: Attacking Chronic Disease Upstream Is the Next Great Inflection

Reitano segments mortality into "fast clock" causes (guns, cars, overdoses) that depress US averages, and the "slow clock" of chronic disease, which drives most deaths and is where the leverage is.

Zach Reitano: "The majority of the way we die is the slow clock, like chronic disease" 00:05:18. And: "health is a precondition to progress." 00:21:38 Looking ahead: "I think we're on the cusp of another shift of that 0 to 1800 where life expectancy was 30. For the last 70 years, we went from 71 to 79." 00:52:49

2. Contrarian Perspectives

Healthcare Should Be 50-70% of GDP

Almost everyone treats rising healthcare spend as a problem to fix. Reitano says the percentage is the wrong metric, and the right target is better outcomes per dollar with spend growing as unit costs fall (Jevons' paradox).

Zach Reitano: "I think it should be as high as possible. 50, 70." 00:01:55 And: "We've never used absolute numbers like that as a problem. The question is are we getting what we want from that dollar amount?" 00:02:31

The US Healthcare System Is Better Than Its Reputation at Acute Care, and Poor Life Expectancy Isn't Mostly Its Fault

Reitano pushes back on the standard "US healthcare is broken everywhere" claim: acute care is world-class, utilization isn't higher, and life-expectancy gaps partly reflect non-healthcare "fast clock" deaths.

Zach Reitano: "If you get cancer, you want to get cancer in the US. If you have a heart attack or a stroke, you want to have it in the US." 00:04:02 And: "we don't use more healthcare than other OECD countries... our prices are higher and our administrative burden is much, much, much higher." 00:04:37

"Healthcare Must Remain Human" Is the Wrong Question; Jobs Must Not Be Prioritized Over Lives

Reitano rejects the input-obsession of protecting human labor, using driverless cars as the test case and stating that obstructers should carry moral weight.

Zach Reitano: "it's an obsession over inputs instead of outcomes." 00:23:26 And: "I do believe that the people impeding driverless cars where they're proven to be safe should have a body count attached to their name, truly." 00:25:49 On the standard for new tech: "It must prove, not that it's 1% better, but that is substantially better than the status quo, but we, as a result, cannot give the status quo a pass." 00:25:49

Kill Long-Term Roadmaps: Plan Nothing Past Six Months

In a fast-changing market, Reitano argues long-term roadmaps are false precision, and he pairs that with sequential (not parallel) building.

Zach Reitano: "Spending a lot of time on long-term roadmaps is like printing out MapQuest instead of using Google Maps. It is false precision." 00:39:32 And: "stubborn on the vision, flexible on the details." 00:39:32

Over 50% of Americans Will Be on a GLP-1 Within 10 Years

Against the current 10-15% penetration, he predicts a majority, citing the clinically eligible base and a statin-style comp.

Zach Reitano: "50+% of people." 00:22:12 The bottoms-up case: "75% of the US population has overweight or has obesity. So, just based on that, that group is clinically eligible." 00:22:19 "I think statins are a good comp." 00:22:52

3. Companies Identified

Ro Telehealth and vertically integrated care/treatment distribution platform; the leading provider of GLP-1s in the US. Reitano's own company, growing from ~$250M to over $3B run rate in four years. Quote: "Ro is the leading provider of GLP-1s in the country. We're probably signing up two, three, four, five times as many patients every single day as our competition." 00:10:52

Eli Lilly GLP-1 manufacturer (and Ro partner). Mentioned as proof that prices fall while volumes surge in the direct-to-consumer model. Quote: "If you look at Lilly's earnings, prices come down, volume far outstrips it." 00:07:30

Novo Nordisk GLP-1 manufacturer integrated with Ro; the comp to Lilly. Quote: "We're integrated with both Novo and Lilly." 00:12:39

Amgen Invented Repatha, the PCSK9-targeting injection, a key example of the genetic-discovery-to-drug pipeline. Quote: "From 2006 to 2015, you have Amgen invent Repatha, a bi-weekly injection." 00:52:49

Merck Invented an oral PCSK9 peptide approved this year, the example of AI-adjacent faster therapeutic discovery. Quote: "They have Merck invent an oral peptide this year that got approved, and it's an oral PCSK9." 00:52:49

Costco Used as an analogy for a demand aggregator with durable economics from membership. Quote: "Costco might be another example where they might have 15% margin on the good itself. They make the majority of their gross profit on a membership." 00:15:01

Huge If True (YouTube channel) Cleo Abram's journalism and explainer channel, which Reitano calls the best on the internet. Quote: "I would actually argue that she's the best journalist on the internet." 00:56:44

Waymo/driverless car companies (unnamed) Cited as the clearest example of outcomes beating the status quo. Quote: "Driverless cars, in pockets, have proven to be 10, 20 times safer than a human driver." 00:24:00

OpenAI and Anthropic Used as analogies for companies riding a generational wave and as a comparison of GLP-1 vs. AI consumer revenue. Quote: "you look at Novo and Lilly to OpenAI and Anthropic. There are many companies, other than OpenAI and Anthropic, that have the same tailwind that didn't ride it to the same extent." 00:38:52

Booz (Booz Allen) Where Reitano was famously fired from a consulting internship, used to illustrate that fit matters. Quote: "I had an internship my junior year of college at Booz... I got fired 4 weeks into the internship." 00:33:14

Dallas Heart Study The genetic cohort study that led to PCSK9 discovery. Quote: "there's a group of people in this study that have a faulty PCSK9 gene, and they have, basically, LDL levels in the 30s to 40s, and they have an 85 to 90% risk reduction of heart disease." 00:51:21

Ramp, Rogo, WorkOS, Vanta, Ridgeline Episode sponsors, each pitched in ad reads as infrastructure for finance, security, compliance, and investment management teams. Quote (Ramp): "Ramp customers grow 3.2 times faster than the average American business." 00:00:00

4. People Identified

Zach Reitano Co-founder and CEO of Ro. Refounded the company in 2022, taking the business 10x with 30% fewer people. Quote: "We've 10x-ed the business with 30% fewer people." 00:36:18

Saman Rahmanian Reitano's co-founder, who runs brand and marketing (the transcript refers to him as Saman). Credited as the superpower behind Ro's celebrity campaigns. Quote: "this is my co-founder Saman's superpower. So, I'm larping when I'm here talking about this. He is absolutely world-class at this." 01:07:37

Rob (Reitano's co-founder) Third co-founder who "passed the baton" during the refounding and remains on the board. Quote: "he passed the baton for the next leg of the relay race... I give him a tremendous amount of credit for doing that and recognizing that." 00:33:48

Reitano's father (a doctor) Reitano's lifelong inspiration; saved his life through navigating a heart procedure and personally A/B-tested a health regimen over 10-15 years. Quote: "I feel like I'm trying to recreate him with software. I'm trying to give him to everyone." 00:46:46

Cleo Abram Reitano's wife; runs the YouTube channel Huge If True. Quote: "she will say, 'When people see a better future, they help build it.'" 00:56:48

Serena Williams Ro Body ambassador for GLP-1s. Quote: "she is one of one as a human being, greatest of all time tennis player. But she's one of millions when it comes to her health journey." 01:00:38

Charles Barkley Ro celebrity ambassador whose commercials are unscripted. Quote: "If you look at a Charles Barkley commercial, it's Charles. It's unscripted." 01:07:37

Megan Fox Ro's ED campaign face, a major permission-structure example. Quote: "Megan Fox, for a certain generation, could tell people to get a colonoscopy, and they'd be like, 'Done.'" 01:00:38

Chrissy Metz and Trisha Paytas Additional authentic-user celebrity ambassadors for Ro. Quote: "when you think about Charles and Chrissy and Serena and Trisha Paytas, and we have two or three coming out soon, all of them are on the product." 01:07:37

Jony Ive Cited as an advocate of sequential over parallel building. Quote: "Jony Ive talks about this, and Frank Slootman talks about this." 00:39:32

Frank Slootman Former Snowflake CEO, cited alongside Ive for focus and sequencing. Quote: same as above. 00:39:30

Ben Thompson Stratechery author whose "demand aggregator" framing Patrick applied to Ro. Quote: "Is demand aggregator sort of the Ben Thompson idea, is that how you think about the business?" 00:15:29

Patrick O'Shaughnessy Host; noted as a Repatha user and the source of the "kindest thing" question that inspired Reitano's answer. Quote: "I take Repatha because my LDL is really high." 00:49:45

5. Operating Insights

Meet Daily at a Fixed Time Until Decisions Are Made

Reitano ran a daily 8:50 a.m. "steer" meeting with the whole leadership team for two straight years, which made it impossible for owners to show up without progress and eliminated week-long drift.

Zach Reitano: "We met every single day at 8:50 for two straight years. Could be 10 minutes, could be 15 minutes... until everything that we needed to do that we needed to align on and decisions that need to be made were made." 00:39:32 And: "You can't show up on Tuesday without having pushed that thing forward." 00:39:32

Build Sequentially, Not in Parallel

Parallel work shows more visible progress across more items in 90 days, but sequential focus compounds better.

Zach Reitano: "it's kind of like only working on the first 10 years of a compound interest curve and never getting to year 30." 00:39:32

Make the "Menu" Explicit and Classify Feedback as Feature or Bug

Reitano uses a restaurant analogy to make culture legible: state what you are, and triage feedback accordingly.

Zach Reitano: "I would tell you, is this a feature or a bug? Try to eliminate bugs, we double down on features." 00:35:08 He also states, "We work one way at Ro. Our what, why, and how is very, very clear." 00:35:43

Don't Confuse Long-Term Vision With Near-Term Strategy

His early-era failure mode was trying to execute the whole vision at once; the remedy was a simple, unchanging vision paired with short-term precision.

Zach Reitano: "we can respond to the data that we see. We can respond to what patients tell us. We can respond to new inventions, to new treatments, to regulatory change." 00:39:32

Invest Disproportionately in Top Talent

After cutting, Ro doubled down on compensation, equity, coaching, and resourcing for the best.

Zach Reitano: "we doubled down on our top talent. From a compensation perspective, from an equity perspective, from a coaching and resourcing perspective, constantly investing in the best people." 00:39:32

Productize Service Failures: Structure Every Side-Effect Message With an SLA

Using LLMs to route and structure every patient message turns an unmeasurable service into a measurable product.

Zach Reitano: "every single time you send a message to Ro that's routed through an LLM, we've analyzed the topic... If you've mentioned a side effect, that side effect gets structured, task is created, it's assigned to a healthcare provider, an SLA is attached, and we have a 24/7 sub-30-minute response time for your side effects." 01:00:38

6. Overlooked Insights

Ro Is Quietly Creating Ground-Truth Patient Data to Personalize Treatment Response

Mentioned in passing, Reitano notes Ro asks why men lose less than women, why people of Hispanic descent lose less than Caucasians, and why some lose 35% of body weight while others lose 5%. That implies a proprietary, vertically integrated dataset across genetics, labs, wearables, and self-reported symptoms, which is a potentially large moat for precision dosing and next-generation drug selection that pharma partners cannot easily replicate.

Zach Reitano: "why do men lose less than women when they're on GLP-1s? Why do people of Hispanic descent lose less than Caucasian people? Why do some people lose 35% of their body weight and other people lose 5? ... You add on genetic data, you add on wearable data, you add on ongoing lab tests, you add on self-reported data." 00:44:11

The Time Horizon Mismatch Is a Structural Argument for Individual, Not Employer, Healthcare Control

Reitano briefly notes that employers optimize for many employees over short tenures while individuals optimize for one lifetime, and that chronic disease is an "area under the curve" problem. Combined, this explains why preventive, long-duration drug regimens are chronically underprovided by the current system and why a consumer-controlled, lifetime-horizon model could unlock a large category of underserved demand.

Zach Reitano: "An employer cares about many employees over a shorter time period than their entire life. An individual cares about themselves and their family over their entire lifetime. That mismatch in incentives will naturally create suboptimal outcomes." 00:18:38 And: "a lot of chronic disease are area under the curve problems. How long do you spend at elevated LDL levels, or how long do you spend with metabolic dysfunction or insulin resistance?" 00:46:46